Company intelligence / Profile preview

Schwarz Pharma

Ownership: Private
Development stage: Other

Overview

Schwarz Pharma marketed a patented drug for Parkinson's disease and had late-stage therapies for Parkinson's disease, epilepsy (notably lacosamide), and restless leg syndrome. It also held a sizable generic drug portfolio including the first generic version of AstraZeneca's Prilosec. At the time of its acquisition by UCB in 2006 for $5.6 billion (€4.4 billion), annual sales were $1.3 billion. Lacosamide was close to regulatory submission with estimated peak sales potential of $1 billion per year.

Therapeutic areas: UrologyNeurology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Pfizer—collaboration on overactive bladder therapy Detrol/tolterodine with royalty arrangements

Beyond the preview

Go deeper on Schwarz Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Schwarz Pharma.

Explore the full profile